EUVIMEDEUVIMED entdecken
Fall-Kontroll-Studie

Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study

Stefania Morganti, Antonio Marra, Sara Gandini, Liliana Ascione, Mariia Ivanova, Konstantinos Venetis, Elham Sajjadi, Paola Zagami, Federica Giugliano, Beatrice Taurelli Salimbeni, Pier Paolo Maria Berton Giachetti, Chiara Corti und 4 weitere

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.113397 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Stefania Morganti und 15 weiteren Autor:innen. Beteiligte Einrichtung: Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, C…. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Estrogen receptor (ER) loss at metastatic relapse occurs in up to 20% of luminal-like primary breast tumors. Data about clinicopathological features associated with ER loss and its prognostic significance are limited. METHODS: In a nested-case-control study, we compared clinicopathological characteristics and clinical outcomes between a cohort of 51 patients with primary ER+ /HER2- and paired triple-negative metastasis (LUM-TN) and two control cohorts of paired early-metastatic ER+ /HER2- (LUM-LUM, n = 50) and triple-negative (TN-TN, n = 49) breast cancers. Stromal tumor-infiltrating lymphocytes (TILs) were assessed according to the TILs Working Group recommendations as continuous and discrete variables with cutoffs (20%, 40%). RESULTS: LUM-TN tumors had lower ER expression than LUM-LUM tumors, but lower grade and Ki67 than TN-TN cases. Median distant-metastasis free survival was similar for LUM-TN and LUM-LUM cohorts, but significantly longer than in TN-TN cases (log-rank P < 0.001). LUM-TN and TN-TN cohorts had a comparable survival from the time of metastatic recurrence, which was significantly shorter than in patients with LUM-LUM tumors (log-rank P < 0.001). High TILs were associated with worse outcomes in patients with ER loss (P < 0.001). CONCLUSIONS: Breast tumors with ER loss at metastatic relapse have intermediate features and outcomes compared with metastatic luminal-like and ab initio triple-negative tumors. Further investigation on the biological mechanisms underpinning the loss of ER expression is ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTriple Negative Breast NeoplasmsHumansFemaleReceptors, EstrogenCase-Control StudiesErb-b2 Receptor Tyrosine KinasesNeoplasm Recurrence, LocalPrognosisRecurrenceReceptors, ProgesteroneBiomarkers, Tumor

Stichwörter der Autor:innen

Breast cancerER lossSubtype switchTumor infiltrating lymphocytes

Substanzen

Receptors, EstrogenErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneBiomarkers, Tumor

Autor:innen und Institutionen

  • Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
  • Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
  • Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Zitieren

APA

Morganti, S., Marra, A., Gandini, S., Ascione, L., Ivanova, M., Venetis, K., Sajjadi, E., Zagami, P., Giugliano, F., Taurelli Salimbeni, B., Berton Giachetti, P. P. M., Corti, C., De Camilli, E., Curigliano, G., Fusco, N., & Criscitiello, C. (2023). Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113397

Vancouver

Morganti S, Marra A, Gandini S, Ascione L, Ivanova M, Venetis K, et al. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.113397

BibTeX
@article{Morganti2023,
  author = {Morganti, Stefania and Marra, Antonio and Gandini, Sara and Ascione, Liliana and Ivanova, Mariia and Venetis, Konstantinos and Sajjadi, Elham and Zagami, Paola and Giugliano, Federica and Taurelli Salimbeni, Beatrice and Berton Giachetti, Pier Paolo Maria and Corti, Chiara and De Camilli, Elisa and Curigliano, Giuseppe and Fusco, Nicola and Criscitiello, Carmen},
  title = {Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.113397}
}
Kostenlos starten →